Clene Inc. (CLNN)
| Market Cap | 76.56M +195.7% |
| Revenue (ttm) | 200,000 -41.5% |
| Net Income | -26.17M |
| EPS | -2.65 |
| Shares Out | 11.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 380,749 |
| Open | 7.28 |
| Previous Close | 7.28 |
| Day's Range | 6.50 - 7.71 |
| 52-Week Range | 2.28 - 13.50 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 33.20 (+410.77%) |
| Earnings Date | May 22, 2026 |
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinde... [Read more]
Financial Performance
In 2025, Clene's revenue was $200,000, a decrease of -41.52% compared to the previous year's $342,000. Losses were -$26.17 million, -33.57% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price target is $33.2, which is an increase of 410.77% from the latest price.
News
Clene price target raised to $50 from $48 at Canaccord
Canaccord raised the firm’s price target on Clene (CLNN) to $50 from $48 and keeps a Buy rating on the shares. The firm noted the company recently announced that it…
Clene Transcript: Emerging Growth Conference 92
FDA feedback supports potential NDA submission for CNM-Au8 in ALS, with neurofilament light reduction as the key surrogate endpoint. Additional funding has been secured, and a phase III MS study is planned for next year.
Clene Announces $7 Million Underwritten Offering of Common Stock
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late cli...
Clene to Present at Upcoming May Conferences
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biophar...
Clene provides update on NDA for ALS following Type C meeting with FDA
Clene (CLNN) announced receipt of final meeting minutes following its recent Type C meeting with the FDA. During the meeting and confirmed in the final meeting minutes, the FDA stated…
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker d...
Clene reports FY25 EPS ($2.65), consensus ($2.35)
Reports FY25 revenue $200k, consensus $152k. “Our next key milestone is the upcoming Type C face-to-face meeting with the U.S. Food and Drug Administration on Clene’s (CLNN) biomarker and survival…
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 ...
Clene Transcript: Emerging Growth Virtual Conference
The company presented compelling clinical data for CNM-Au8 in ALS, showing significant biomarker and survival benefits, and is preparing for a key FDA meeting by end of Q1. NDA filing is targeted for Q2, with commercialization possible in early 2027, supported by recent financing.
Clene issues letter to shareholders on CNM-Au8 2026 catalysts
Clene (CLNN) and its wholly owned subsidiary Clene Nanomedicine issued a letter to stockholders outlining key anticipated regulatory and clinical milestones for CNM-Au8 in 2026. “AFollowing the comple...
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-...
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene Transcript: Emerging Growth Conference 89
A pivotal FDA meeting this quarter will review biomarker and survival data supporting accelerated approval for an ALS therapy, with NDA filing targeted for Q2 and possible commercialization early next year. Recent financing extends runway, backed by major healthcare investors.
Clene announces additional CNM-Au8 biomarker data for potential NDA filing
Clene (CLNN) announced that the U.S. Food and Drug Administration, FDA, has granted Clene an in-person Type C Meeting later this quarter. Key highlights: The FDA has granted an in-person…
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late cli...
Clene announces over $28M registered direct offering
Clene (CLNN) announced a registered direct offering priced above market under Nasdaq rules of over $28M by new and existing investors. On January 9, 2026, Clene entered into securities purchase…
Clene Announces Registered Direct Offering of Over $28 Million
Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo Capital Initial financing tranche...
Clene Transcript: Emerging Growth Conference 88
Clene is advancing its lead ALS therapy, CNM-Au8, toward accelerated FDA approval using biomarker data, with a New Drug Application planned for the first half of the year. If successful, commercialization could occur by late 2026 or early 2027, addressing a major unmet need.
Clene price target raised to $30 from $20 at Maxim
Maxim analyst Naz Rahman raised the firm’s price target on Clene (CLNN) to $30 from $20 and keeps a Buy rating on the shares after the company and its wholly…
Clene Transcript: Study Update
Significant reductions in neurofilament and GFAP biomarkers with CNM-Au8 correlated with improved survival in ALS, especially in advanced and bulbar onset patients. The FDA is considering these biomarkers as surrogate endpoints for accelerated approval, and a Phase 3 trial with survival as the primary endpoint is planned.
Clene announces significant reductions in NfL, GFAP when treated with CNM-Au8
Clene (CLNN) and its wholly owned subsidiary Clene Nanomedicine announced completion of the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS. The results demonstrate statistica...
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, r...
Clene to Provide CNM-Au8® ALS Program Update
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace...
Clene reports Q3 EPS (85c), consensus (56c)
Reports Q3 revenue $15,000, consensus $55,140. “The three potential biomarker paths that could be leveraged to increase the persuasiveness of our ALS data, as outlined by the FDA, include: the…